United Therapeutics Corp UTHR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/26/21 EST
167.18UNCH (UNCH)
Volume
8,547
Close
167.18quote price arrow down-1.62 (-0.96%)
Volume
331,308
52 week range
75.58 - 181.14

...

Loading . . .

KEY STATS

  • Open169.79
  • Day High170.26
  • Day Low165.99
  • Prev Close167.18
  • 52 Week High181.14
  • 52 Week High Date02/24/21
  • 52 Week Low75.58
  • 52 Week Low Date03/18/20
  • Market Cap7.446B
  • Shares Out44.54M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.40
  • 1 Year % Change65.87

RATIOS/PROFITABILITY

  • EPS (TTM)11.56
  • P/E (TTM)14.46
  • Fwd P/E (NTM)13.13
  • EBITDA (MRQ)643.50M
  • ROE (MRQ)16.67%
  • Revenue (MRQ)1.483B
  • Gross Margin (MRQ)92.71%
  • Net Margin (MRQ)34.71%
  • Debt To Equity (MRQ)23.56%

EVENTS

  • Earnings Date04/27/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest United Therapeutics Corp News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and...
Martine Rothblatt Ph.D. J.D.
Chairman
Christopher Patusky J.D.
Vice Chairman
Michael Benkowitz
President
James Edgemond
Chief Financial Officer
Paul Mahon J.D.
Executive Vice President
Address
1040 SPRING ST
Silver Spring, MD
20910
United States